Protalix BioTherapeutics, Inc.
PLX
$1.68
$0.010.30%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 5.39M | 6.28M | 3.91M | 2.93M | -9.61M |
| Total Depreciation and Amortization | 1.41M | 1.37M | 1.33M | 1.30M | 1.28M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 59.00K |
| Total Other Non-Cash Items | 2.48M | 4.02M | 3.31M | 3.63M | 4.51M |
| Change in Net Operating Assets | -19.32M | -13.86M | -9.11M | 811.00K | 12.03M |
| Cash from Operations | -10.03M | -2.20M | -572.00K | 8.67M | 8.28M |
| Capital Expenditure | -1.66M | -1.25M | -990.00K | -1.28M | -1.11M |
| Sale of Property, Plant, and Equipment | 0.00 | 3.00K | 3.00K | 3.00K | 3.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -14.91M | 5.50M | 5.50M | 5.50M | 20.30M |
| Cash from Investing | -16.57M | 4.26M | 4.52M | 4.22M | 19.20M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00 | -20.42M | -20.42M | -20.42M | -20.42M |
| Issuance of Common Stock | 12.81M | 12.81M | 8.70M | 3.63M | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 12.81M | -7.61M | -11.72M | -16.79M | -20.42M |
| Foreign Exchange rate Adjustments | 38.00K | 48.00K | 24.00K | 25.00K | -56.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.76M | -5.50M | -7.75M | -3.87M | 7.00M |